Home
Live Updates
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China : comparemela.com
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization
China NMPA approval based on...
Related Keywords
Japan ,
Macau ,
Laos ,
Philippines ,
Hong Kong ,
Cambodia ,
Taiwan ,
New Zealand ,
Vietnam ,
Republic Of ,
Indonesia ,
Australia ,
Thailand ,
United States ,
Singapore ,
China ,
Malaysia ,
Chinese ,
Harald Reinhart ,
Matt Ronsheim ,
Acinetobacter Baumannii ,
Centers For Disease ,
Head Of Global Development ,
Zai Lab Limited ,
Zai Lab ,
Securities Exchange ,
Innoviva Inc ,
Drug Administration ,
Zai Lab Forward ,
Exchange Commission ,
Jolla Pharmaceutical Company ,
Entasis Therapeutics Inc ,
Zai Lab New Drug Application ,
World Health Organization ,
China National Medical Products Administration ,
Innoviva Specialty Therapeutics ,
National Medical Products Administration ,
New Drug Application ,
Global Development ,
Infectious Diseases ,
Innoviva Specialty ,
Greater China ,
Disease Control ,
Acinetobacter Baumannii Infections ,
Full Prescribing Information ,
Private Securities Litigation Reform Act ,
Specialty Therapeutics ,
Specialty Therapeutic ,
Securities Exchange Act ,
Financial Condition ,
Annual Report ,
Quarterly Reports ,
Risk Factors ,
Clinical Presentation ,
Molecular Bacterial Pathogenesis Volume ,
Antimicrobial Resistance ,
Rev Drug ,
Antibiotic Resistance ,
Patient Safety ,
China Diagnosis ,
Treatment Guideline ,
comparemela.com © 2020. All Rights Reserved.